Anti-phospholipid antibodies (aPL) detected in the sera of patients with APS are mainly directed against beta2-glycoprotein I (β2GPI), currently considered the most relevant target antigen of aPL (5, 6). This evidence concerns the gene APOH and autoimmune polyendocrinopathy.